Stockpiling of H5N1 vaccines

Size: px
Start display at page:

Download "Stockpiling of H5N1 vaccines"

Transcription

1 Stockpiling of H5N1 vaccines Norbert W. Hehme EVM Influenza Pandemic Working Group EU-Commission Workshop on Stockpiling of Medicinal Products February 21/22, 2008

2 European Vaccine Manufacturers 1 (EVM) Represents major European vaccine producers 2 : - manufacturing 9.7 billions s per year to improve public health around the world - investing in 137 vaccine R&D projects Major partner in improving global public health by targeting all major vaccine preventable disease around the world Largest worldwide suppliers of vaccines (48% of exports goes to developing countries) Europe is at the heart of the world vaccine industry which represents a strategic asset for Europe 1 EVM members are: Baxter, Berna (Crucell), GlaxoSmithkline Biologicals, Novartis Vaccines, Sanofi Pasteur, Sanofi Pasteur MSD, Solvay and Wyeth. 2 EVM data

3 Pandemic preparedness options Three major challenges for effective vaccination Protection throughout Pandemic Protection as early as possible Ensuring sufficient vaccine supply World-wide Pandemic Manufacturing before pandemic and stockpile Vaccine Manufacturing during pandemic Pandemic Vaccine Pre-Pandemic Vaccine 3

4 Timelines pandemic vaccine production WHO reference centers Producers Week Declaration of pandemia by WHO Choice of the candidate strain for the production of the vaccine Preparation of the reassortant candidate strain Candidate strain available from the reference centers Reagents for HA quantification available Preparation of production sites Stop production of inter-pandemic vaccine Production of primary seed lot Control of primary seed lot Production of working seed lot Control of working seed lot Production of the first monovalent batch Control of the first monovalent batch Vaccine formulation Control of final monovalent bulk vaccine Filling of the vaccine Control of filled product Packaging Control of final product Local AuthoritiesRelease of final product 12 weeks time gap between arrival of pandemic vaccine strain and availability of first pandemic vaccine s (provided potency test reagents will be available 7 weeks after strain arrival) 4

5 Key factors for vaccine stockpiles Vaccine stockpiles help Pandemic Preparedness in several ways : Offer the potential for early protection Ease the logistical load therefore establish the logistical systems for large stockpiles Registration of pandemic and pre-pandemic vaccines via 2 regulatory procedures (core dossier, flu vaccines from viruses with the potential to cause a pandemic) Quick availability of strains and reagents is key Many remaining technical issues: Clade changes and requested data (quality, pre-clinical and clinical) How to maintain all clades available with a simple procedure (not having one dossier per strain) Manufacturing yields different per clade Maintaining the annual seasonal production Stability of stockpiles Several countries started stockpiling even without existing registration* 5 * USA, UK, Australia, Finland, France, Italy, Switzerland, Japan

6 Pathways to pandemic preparedness Human to Human Transmission 0 +/ World-wide H5N1 Pandemic Phase 3 Phase 4 Phase 5 Phase 6 : PANDEMIC Advance Purchase Agreement 1 st 2 nd Protection Advance Production Agreement & Stockpile 1 st 2 nd Protection Stockpile and Targeted Use 1 st 2 nd Cross Protection 3 rd Protection Options Pre-Pandemic Vaccine Pandemic Vaccine 6

7 Logistical aspects Stockpiles will consist of different vaccines Need for harmonized packaging Rules needed to avoid mix-up + allow product identification Variability of presentations (2 vial concept, 1 vial concept, mono, multi- ) Stockpiles must be maintained/updated over time Allow for easy replacement of components Stockpiling of additional components is critical Syringes Needles Packaging materials for distribution Industry needs to deliver vaccine Other components to be provided by parties outside industry 7

8 Warehouse requirements Warehouses must be Temperature controlled (2-8ºC) cgmp compliant Systems and qualified resources needed for Routine follow up of temperature registrations and GMP conditions Criteria and action in case of deviations Personnel training and qualification To be supervised by a Qualified Person Protection measures mandatory Prevent intrusion of people in panic Prevent damage by the elements (rains, flooding etc) Assure access by authorized persons only Conditions needed to avoid mix up of products Organized to allow stock replacements Depending on shelf life, batches need to be replaced Different replacement of antigen + adjuvant Structured to allow rapid stock deployment 8

9 Deployment of stockpiled vaccines Rapid distribution is key Need for easy access to transport infrastructure Complete infrastructure to be established up-front Maintaining cold chain during distribution and transport Decision to start distribution To be management centrally (EU vs country level) According to strict rules Final deployment within regions/areas up to administration to patient is not a given Need for development of robust area deployment procedures and systems Appropriate administration of usage for tracking, reporting and follow up in central/national databases Need for adequate communication Development of EU guidelines in collaboration with ECDC and WHO 9

10 Summary and conclusions Vaccine industry remains committed to work with EU and Member States Continued and intensified communication is mandatory EC / ECDC / WHO / Industry Stockpiling vaccines + antivirals remain only reliable tools to fight against first wave of a pandemic Restrictions to guarantee timely availability of products following declaration of a pandemic alert EU decisions needed on central vs national stockpiles National stockpiling efforts already in place Joined responsibilities on stockpiling Industry in charge of delivering vaccines Syringes, needles etc. to be provided by the public sector Complete infrastructure for building and deploying stocks to be established Free trade of products (keeping borders open) is essential 10

Human H5N1 and Pandemic Vaccines Practicalities of Production: A perspective from Industry

Human H5N1 and Pandemic Vaccines Practicalities of Production: A perspective from Industry Human H5N1 and Pandemic Vaccines Practicalities of Production: A perspective from Industry Luc Hessel M.D. Pandemic Influenza Working Group European Vaccine Manufacturers 4th Joint EC/ECDC/WHO Workshop

More information

Expedited procedure for evaluating pandemic influenza A (H1N1) 2009 vaccines

Expedited procedure for evaluating pandemic influenza A (H1N1) 2009 vaccines Expedited procedure for evaluating pandemic influenza A (H1N1) 2009 vaccines Preamble On 11 June 2009, WHO declared an influenza pandemic caused by influenza A (H1N1) 2009 virus 1. On 13 July 2009, WHO

More information

FLUSECURE A consortium of European Health Institutes with vaccine development capabilities February 2006 August 2010

FLUSECURE A consortium of European Health Institutes with vaccine development capabilities February 2006 August 2010 FLUSECURE A consortium of European Health Institutes with vaccine development capabilities February 2006 August 2010 Partners Jan Hendriks E-mail: jan.hendriks@rivm.nl 15-16 October 2012 Luxembourg Netherlands

More information

U.S. Readiness for Pandemics

U.S. Readiness for Pandemics 0 U.S. Readiness for Pandemics 5 th National Emergency Management Summit Brooklyn, NY September 15, 2011 Robin Robinson, Ph.D. Deputy Assistant Secretary for Preparedness & Response (HHS/ASPR) Director

More information

Request for Letters of Intent. International Development of H5N1 Influenza Vaccines

Request for Letters of Intent. International Development of H5N1 Influenza Vaccines Request for Letters of Intent International Development of H5N1 Influenza Vaccines The World Health Organization (WHO) intends to provide funding to developing (1) country vaccine manufacturers to develop

More information

Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine. since 2006

Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine. since 2006 Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine use from high to low income countries since 2006 Dr. Michael Watson, sanofi-pasteur on behalf of WHO GAP

More information

IFPMA IVS ITF Background Paper The WHO System for Influenza Surveillance and Supply of Viruses for the Standardized Production of Influenza Vaccines

IFPMA IVS ITF Background Paper The WHO System for Influenza Surveillance and Supply of Viruses for the Standardized Production of Influenza Vaccines The WHO System for Influenza Surveillance and Supply of Viruses for the Standardized Production of Influenza Vaccines BACKGROUND Chemin Louis-Dunant 15, P.O., Box 195, 1211 Geneva 20, Switzerland Tel:

More information

Ensuring an Adequate Stockpile of Antivirals. Paul Brown F. Hoffmann La-Roche Basel, Switzerland

Ensuring an Adequate Stockpile of Antivirals. Paul Brown F. Hoffmann La-Roche Basel, Switzerland Ensuring an Adequate Stockpile of Antivirals Paul Brown F. Hoffmann La-Roche Basel, Switzerland Vaccines and Antivirals Vaccines provide the best prevention option But there are limitations: Time from

More information

SANOFI PASTEUR, LEADING PROVIDER OF SEASONAL INFLUENZA VACCINES

SANOFI PASTEUR, LEADING PROVIDER OF SEASONAL INFLUENZA VACCINES FACT SHEET SANOFI PASTEUR, LEADING PROVIDER OF SEASONAL INFLUENZA VACCINES WORLD S LEADING INFLUENZA VACCINE MANUFACTURER Annual production capacity of Sanofi Pasteur seasonal influenza vaccines have doubled

More information

Adjuvant technology transfer hub

Adjuvant technology transfer hub Adjuvant technology transfer hub An example of transferring «enabling technologies» Nicolas Collin, DVM, PhD Vaccine Formulation Laboratory, University of Lausanne WH Collaborating Centre Workshop on Technology

More information

Pandemic lessons learnt

Pandemic lessons learnt Pandemic lessons learnt PCWP-HCPWG Joint meeting 28 February 2012 Presented by: Ragini Shivji, Monika Benstetter EMA An agency of the European Union Overview of presentation Background & Objective European

More information

Towards a Sustainable Global Infrastructure for Medical Countermeasures

Towards a Sustainable Global Infrastructure for Medical Countermeasures Towards a Sustainable Global Infrastructure for Medical Countermeasures Institute of Medicine The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from

More information

Pandemic Influenza Preparedness

Pandemic Influenza Preparedness Pandemic Influenza Preparedness Of the many health threats that we are preparing for, this is the one that we know will happen. Bruce G. Gellin, MD, MPH Director, National Vaccine Program Office Department

More information

Page 1 of 5 For Immediate Release Office of the Press Secretary July 17, 2007 Fact Sheet: Implementation of the National Strategy for Pandemic Influenza A One-Year Summary Of Efforts To Better Protect

More information

WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES

WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES SURVEY QUESTIONNAIRE A.1. Introduction The Global Action Plan for Influenza Vaccines (GAP) was launched in 2006 as a ten year initiative to address the anticipated

More information

Michel BAIJOT Vice President, WW Business Development & Strategic Alliances

Michel BAIJOT Vice President, WW Business Development & Strategic Alliances Technology Transfer and Vaccines: The GSK Experience WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Geneva, November 30th, 2010 Michel BAIJOT Vice President, WW Business

More information

Financing Influenza Vaccine R&D

Financing Influenza Vaccine R&D Financing Influenza Vaccine R&D WHO GAP-II Geneve, Switzerland July 13, 2011 Robin Robinson, Ph.D. Deputy Assistant Secretary & Director HHS/ASPR/BARDA 0 Vaccine Development is Risky, Lengthy, & Expensive

More information

Global Challenges of Pandemic and Avian Influenza. 19 December 2006 Keiji Fukuda Global influenza Programme

Global Challenges of Pandemic and Avian Influenza. 19 December 2006 Keiji Fukuda Global influenza Programme Global Challenges of Pandemic and Avian Influenza 19 December 2006 Keiji Fukuda Global influenza Programme Summary of Current H5N1 Situation 1997 First known outbreak infecting humans 18 people hospitalized

More information

Annex 5. Generic protocol for the calibration of seasonal and pandemic influenza antigen working reagents by WHO essential regulatory laboratories

Annex 5. Generic protocol for the calibration of seasonal and pandemic influenza antigen working reagents by WHO essential regulatory laboratories Annex 5 Generic protocol for the calibration of seasonal and pandemic influenza antigen working reagents by WHO essential regulatory laboratories Abbreviations 262 1. Introduction 262 2. Essential regulatory

More information

What public health benefits could be secured by using universal labelling & packaging for influenza pandemic vaccines?

What public health benefits could be secured by using universal labelling & packaging for influenza pandemic vaccines? What public health benefits could be secured by using universal labelling & packaging for influenza pandemic vaccines? Workshop on the joint procurement of medical countermeasures 29 April 2015, Luxembourg

More information

Global Pandemic Preparedness Research Efforts. Klaus Stöhr. WHO Global Influenza Programme. Today

Global Pandemic Preparedness Research Efforts. Klaus Stöhr. WHO Global Influenza Programme. Today Global Pandemic Preparedness Research Efforts Klaus Stöhr 3 Today Medium-term applied research linked to medical and public health interventions addressing the current pandemic situation in Asia Natural

More information

Seasonal vaccine approval - EUROPEAN UNION -

Seasonal vaccine approval - EUROPEAN UNION - Seasonal vaccine approval - EUROPEAN UNION - Jim Robertson National Institute for Biological Standards and Control National Institute for Biological Standards and Control Assuring the quality of biological

More information

COMMISSION OF THE EUROPEAN COMMUNITIES COMMISSION STAFF WORKING DOCUMENT. Vaccination strategies against pandemic (H1N1) 2009.

COMMISSION OF THE EUROPEAN COMMUNITIES COMMISSION STAFF WORKING DOCUMENT. Vaccination strategies against pandemic (H1N1) 2009. COMMISSION OF THE EUROPEAN COMMUNITIES Brussels, 15.9.2009 SEC(2009) 1189 final COMMISSION STAFF WORKING DOCUMENT Vaccination strategies against pandemic (H1N1) 2009 accompanying the COMMUNICATION FROM

More information

Promoting Public Health Security Addressing Avian Influenza A Viruses and Other Emerging Diseases

Promoting Public Health Security Addressing Avian Influenza A Viruses and Other Emerging Diseases Promoting Public Health Security Addressing Avian Influenza A Viruses and Other Emerging Diseases Masaya Kato, WHO Viet Nam OIE Regional Workshop on Enhancing Influenza A viruses National Surveillance

More information

Guideline on influenza vaccines submission and procedural requirements

Guideline on influenza vaccines submission and procedural requirements 1 2 3 October 2014 EMA/56793/2014 Human Medicines Research and Development Support 4 5 6 Guideline on influenza vaccines submission and procedural requirements Regulatory and procedural requirements module

More information

Plant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing

Plant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing Plant-Derived Influenza Virus-Like Particles: A Unique Combination of Highly Effective Product and Cost-Effective Manufacturing Nathalie Charland, PhD GHSI Workshop on Public Health Emergency Medical Countermeasures

More information

Approaches to Pandemic Influenza Vaccine Preparedness

Approaches to Pandemic Influenza Vaccine Preparedness United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Approaches to Pandemic Influenza Vaccine Preparedness Julie Schafer, MPH, MS Influenza

More information

ECDC meeting report: IVth Joint EC/ECDC/WHO Workshop on Pandemic Influenza Preparedness Luxembourg, September 2007

ECDC meeting report: IVth Joint EC/ECDC/WHO Workshop on Pandemic Influenza Preparedness Luxembourg, September 2007 ECDC meeting report: IVth Joint EC/ECDC/WHO Workshop on Pandemic Influenza Preparedness Luxembourg, 25-27 September 2007 Luxembourg became the focus of attention for the 4 th Joint EC/ECDC/WHO Workshop

More information

Pandemic report and lessons learned

Pandemic report and lessons learned 29 April 2011 EMA/221017/2011 Patient Health Protection ess Pandemic report and lessons learned Outcome of the European Medicines Agency's activities during the 2009 (H1N1) flu pandemic 7 Westferry Circus

More information

WHO HHS Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing

WHO HHS Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing WHO HHS Workshop on Business Modeling for Sustainable Influenza Vaccine Manufacturing Washington, DC January 14th 16th, 2013 Session 4: Attracting Investments and Generating Revenue Theory, Practice and

More information

Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries.

Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Managing cost considerations and access to technology for cost effective vaccine manufacture in developing countries. Amol R. Dindokar Serum Institute of India ltd. Overview Disease Control Priorities

More information

FINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA

FINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA Comprehensive Family Immunization Family and Community Health Area FINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA TECHNICAL ADVISORY GROUP ON VACCINE-PREVENTABLE DISEASES 24-26 AUGUST 2009, COSTA RICA Epidemiological

More information

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure

Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure 1 2 3 4 5 6 7 8 9 14 April 2010 EMA/CHMP/BWP/99698/2007 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Procedural advice on the submission of variations for annual update of human influenza

More information

Update on A(H1N1) pandemic and seasonal vaccine availability. July 7, 2009

Update on A(H1N1) pandemic and seasonal vaccine availability. July 7, 2009 Update on A(H1N1) pandemic and seasonal vaccine availability July 7, 2009 Presentation objectives and approach Presentation Objectives Review production status for 2009-2010 Northern Hemisphere vaccine

More information

1. Avian Influenza H5N1 had not occurred in Malaysia until the first case of

1. Avian Influenza H5N1 had not occurred in Malaysia until the first case of INTERVENTION NOTES BY H.E. AMBASSADOR HAMIDON ALI, PERMANENT REPRESENTATIVE OF MALAYSIA TO THE UNITED NATIONS AT THE SPECIAL EVENT ON THE THEME OF AVIAN FLU, ORGANIZED BY THE ECONOMIC AND SOCIAL COUNCIL

More information

Vaccines of today and products needed for the short-, intermediate- and longterm. OIE/FAO OFFLU Conference Beijing China December 4-6, 2013

Vaccines of today and products needed for the short-, intermediate- and longterm. OIE/FAO OFFLU Conference Beijing China December 4-6, 2013 Vaccines of today and products needed for the short-, intermediate- and longterm XU, Wei-Cheng OIE/FAO OFFLU Conference Beijing China December 4-6, 2013 1 Influenza A reservoir & transmission H3N8, (H5N1)

More information

100 years of Influenza Pandemic and the prospects for new influenza vaccines

100 years of Influenza Pandemic and the prospects for new influenza vaccines 100 years of Influenza Pandemic and the prospects for new influenza vaccines Dr John McCauley Director, WHO Collaborating Centre for Reference and Research on influenza The Francis Crick Institute London

More information

GSK s Candidate Influenza A (H5N1) Virus Monovalent Vaccine

GSK s Candidate Influenza A (H5N1) Virus Monovalent Vaccine GSK s Candidate Influenza A (H5N1) Virus Monovalent Vaccine Regulatory Pathway for Licensure VRBPAC, February 29, 2012 Katalin Abraham, Director, US Regulatory Affairs GSK Biologicals GSK s Influenza Vaccines

More information

Pandemic Influenza Preparedness and Response

Pandemic Influenza Preparedness and Response 24 th Meeting of Ministers of Health Dhaka, Bangladesh, 20-21 August 2006 SEA/HMM/Meet.24/4(b) 10 July 2006 Pandemic Influenza Preparedness and Response Regional situation: Human cases and outbreaks of

More information

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell

More information

20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus since April 2009.

20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus since April 2009. B. UPDATE ON THE PANDEMIC (H1N1) 2009 CD50/INF/6 (Eng.) - 7 - Annex B Background 20. The purpose of this document is to examine the pre-pandemic efforts and the response to the new influenza A (H1N1) virus

More information

The OIE World Animal Health and Welfare Fund

The OIE World Animal Health and Welfare Fund The OIE World Animal Health and Welfare Fund Alain Dehove (DVM, MSc) Coordinator of the OIE World Fund a.dehove@oie.int OIE World Animal Health & Welfare Fund Created in 2004 by a resolution voted by OIE

More information

7th Mena Influenza Stakeholders Meeting. WHO Influenza Strategy Development and Vaccine-related Research Priorities

7th Mena Influenza Stakeholders Meeting. WHO Influenza Strategy Development and Vaccine-related Research Priorities 7th Mena Influenza Stakeholders Meeting WHO Influenza Strategy Development and Vaccine-related Research Priorities Wenqing Zhang 9 10 September 2017 Riga, Latvia 1 Seasonal influenza 1 billion cases yearly

More information

(EISS) and its future 4 th Joint EC/ECDC/WHO workshop Pandemic Influenza Preparedness Luxembourg, September 2007

(EISS) and its future 4 th Joint EC/ECDC/WHO workshop Pandemic Influenza Preparedness Luxembourg, September 2007 (EISS) and its future 4 th Joint EC/ECDC/WHO workshop Pandemic Preparedness Luxembourg, 25-27 September 2007 Koos van der Velden Adam Meijer History WHO global network of National Centres (NIC) since 1949

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) European Medicines Agency Veterinary Medicines and Inspections London, 16 February 2006 Doc. Ref.EMEA/CVMP/IWP/46853/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP) REFLECTION PAPER: MINIMUM

More information

Questions and Answers

Questions and Answers Questions and Answers Recommended composition of influenza virus vaccines for use in the southern hemisphere 2016 influenza season and development of candidate vaccine viruses for pandemic preparedness

More information

Updated: 26 August 2010

Updated: 26 August 2010 Australian Technical Advisory Group on Immunisation (ATAGI) Updated advice on the use of pandemic and seasonal influenza vaccines in children

More information

Preparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do

Preparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do Preparing For Pandemic Influenza: What the CDC and HHS Recommend You Can Do Based on current data and information from the Centers for Disease Control (CDC) and the U.S. Department Health and Human Services

More information

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) <DRAFT>

COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) <DRAFT> European Medicines Agency London, 24 July 2006 Doc. Ref. EMEA/CHMP/VWP/263499/2006 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) GUIDELINE ON DOSSIER STRUCTURE AND CONTENT OF MARKETING AUTHORISATION

More information

Pandemic Influenza Preparedness Framework. Sharing influenza viruses & access to vaccines and other benefits

Pandemic Influenza Preparedness Framework. Sharing influenza viruses & access to vaccines and other benefits Pandemic Influenza Preparedness Framework Sharing influenza viruses & access to vaccines and other benefits What is PIP? Landmark, innovative public health arrangement to increase global preparedness to

More information

The Inclusion of Seasonal Influenza Viruses and Genetic Sequence Data (GSD) in the Context of the Pandemic Influenza Preparedness (PIP) Framework

The Inclusion of Seasonal Influenza Viruses and Genetic Sequence Data (GSD) in the Context of the Pandemic Influenza Preparedness (PIP) Framework The Inclusion of Seasonal Influenza Viruses and Genetic Sequence Data (GSD) in the Context of the Pandemic Influenza Preparedness (PIP) Framework A position paper from the Directors of the GISRS WHO Collaborating

More information

WHO/PQT Updates on WHO Prequalification Priorities and Regulatory Systems Strengthening work

WHO/PQT Updates on WHO Prequalification Priorities and Regulatory Systems Strengthening work WHO/PQT Updates on WHO Prequalification Priorities and Regulatory Systems Strengthening work Dr Drew Meek Prequalification Team Regulation of Medicines and other Health Technologies Essential Medicines

More information

Pandemic (H1N1) 2009 influenza vaccination in the EU

Pandemic (H1N1) 2009 influenza vaccination in the EU Pandemic (H1N1) 2009 influenza vaccination in the EU Dr Antoon Gijsens Unit C3 - Health Threats Directorate C - Public Health and Risk Assessment Directorate-General for Health & Consumers Luxembourg,

More information

GSK commitment to influenza prevention

GSK commitment to influenza prevention GSK commitment to influenza prevention Dr Catia Ferreira Influenza Portfolio US Medical Affairs Leader GSK Vaccines GSK commitment to Influenza Rixensart (Belgium) Shenzhen (China) Marietta (US) Saint-Amand

More information

Pandemic Influenza Cross Sectoral Preparedness and Planning

Pandemic Influenza Cross Sectoral Preparedness and Planning Opening statement Seminar on Pandemic Influenza Cross Sectoral Preparedness and Planning Ministry of Health and Care Services, Oslo 19. February 2009 State secretary Rigmor Aasrud Dear speakers, dear participants,

More information

H1N1 Vaccine Based on CDCs ACIP Meeting, July 29, 2009

H1N1 Vaccine Based on CDCs ACIP Meeting, July 29, 2009 August 6, 2009 H1N1 Vaccine Based on CDCs ACIP Meeting, July 29, 2009 CDC s Advisory Committee on Immunization Practices (ACIP), a panel made up of medical and public health experts, met July 29, 2009,

More information

An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too)

An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too) An Affordable Pandemic Influenza Vaccine Solution for Developing Countries (and Developed Countries Too) James M. Robinson, PE VP Technical and Quality Operations Novavax, Inc. New Cells for New Vaccines

More information

Vaccines: (inter)national regulation and quality in resource limited settings

Vaccines: (inter)national regulation and quality in resource limited settings Vaccines: (inter)national regulation and quality in resource limited settings Raffaella Ravinetto QUAMED Research & Networking Institute of Tropical Medicine Antwerp 12th July 2017 Based on a presentation

More information

Planning for Pandemic Influenza

Planning for Pandemic Influenza Planning for Pandemic Influenza John Kobayashi Faculty, Northwest Center for Public Health Practice, Foreign Advisor with the Field Epidemiology Training Program in Japan Pandemic Influenza as a Paradigm

More information

Multi-sectoral aspects of pandemic preparedness and response

Multi-sectoral aspects of pandemic preparedness and response Multi-sectoral aspects of pandemic preparedness and response Best practices, challenges and lessons learned in the EU International Ministerial Conference on Avian & Pandemic Influenza Sharm el Sheikh,

More information

USG Policy Perspectives on Global Influenza

USG Policy Perspectives on Global Influenza USG Policy Perspectives on Global Influenza IOM Committee for the Assessment of DoD-GEIS Influenza Surveillance & Response Programs Ms. Ellen P. Embrey Deputy Assistant Secretary of Defense Force Health

More information

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer

Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int Part 1: General information Name of Manufacturer Prequalification Team WHO PUBLIC INSPECTION

More information

a major Public Health & Technology Transfer challenge

a major Public Health & Technology Transfer challenge Manufacturing Flu vaccine in Mexico: a major Public Health & Technology Transfer challenge Roger Vinas - Vaccine Technology III - June 2010 Agenda 1. Flu vaccine, made in Mexico: 1.1 The Mexican Public

More information

Draft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009

Draft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009 15 March 2010 EMA/CVMP/IWP/105506/2007 Committee for medicinal products for veterinary use (CVMP) Guideline on data requirements for multi-strain dossiers for inactivated vaccines against avian influenza

More information

100 Years since the 1918 Spanish Flu Pandemic. Current Standards for Flu Pandemic Preparedness

100 Years since the 1918 Spanish Flu Pandemic. Current Standards for Flu Pandemic Preparedness 100 Years since the 1918 Spanish Flu Pandemic. Current Standards for Flu Pandemic Preparedness OCTOBER 16, 2018 SALLY A. HOJVAT M.Sc., Ph.D. Retired as Director of FDA Division of Microbiology Devices,

More information

Developing a novel Group B Streptococcus (GBS) Vaccine. Patrick Tippoo

Developing a novel Group B Streptococcus (GBS) Vaccine. Patrick Tippoo Developing a novel Group B Streptococcus (GBS) Vaccine Patrick Tippoo Presentation 1. Overview of Biovac 2. GBS Project Overview 3. African Significance Biovac Overview A Centre of Excellence rooted in

More information

WORLD BANK RESPONSE TO INFLUENZA A(H1N1) Rakesh Nangia Director, Strategy & Operations Human Development Network

WORLD BANK RESPONSE TO INFLUENZA A(H1N1) Rakesh Nangia Director, Strategy & Operations Human Development Network WORLD BANK RESPONSE TO INFLUENZA A(H1N1) Rakesh Nangia Director, Strategy & Operations Human Development Network Tokyo, July 2009 World Bank Response to A(H1N1) Influenza A(H1N1) Global Health and Risks

More information

The Impact of Pandemic Influenza on Public Health

The Impact of Pandemic Influenza on Public Health This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC

Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute

More information

Advancing Pandemic Preparedness through APSED III

Advancing Pandemic Preparedness through APSED III Advancing Pandemic Preparedness through APSED III Masaya Kato Programme Area Manager Country Health Emergency Preparedness and the IHR (CPI) WHO Health Emergencies Programme (WHE) WHO Western Pacific Regional

More information

Globalization and Health The regional response

Globalization and Health The regional response Zsuzsanna Jakab Director European Centre for Disease Prevention and Control (ECDC) IBA Annual Meeting Anthrax, SARS and Bioweaponry Is Globalisation Bad for Your Health? 28 September 2005, Prague Globalization

More information

Universal Influenza Vaccine One For All

Universal Influenza Vaccine One For All Universal Influenza Vaccine One For All MIXiii Conference, May 2014 Forward Looking Statements 2 This presentation includes forward-looking statements within the meaning of applicable securities laws.

More information

Adopted by CVMP 10 March Date for coming into effect 1 July Revised draft guideline agreed by Immunologicals Working Party 22 June 2017

Adopted by CVMP 10 March Date for coming into effect 1 July Revised draft guideline agreed by Immunologicals Working Party 22 June 2017 1 2 3 7 September 2017 EMA/CVMP/IWP/105506/2007-Rev.1 Committee for medicinal products for veterinary use (CVMP) 4 5 6 7 Guideline on data requirements for multi-strain dossiers for inactivated vaccines

More information

PIP Framework Information Session 10 April 2018

PIP Framework Information Session 10 April 2018 Pandemic Influenza Preparedness Framework Sharing of influenza viruses & access to vaccines and other benefits PIP Framework Information Session 10 April 2018 PIP Framework Information Session Purpose:

More information

WASHINGTON, DC

WASHINGTON, DC OFFICE OF THE ASSISTANT SECRETARY OF DEFENSE WASHINGTON, DC 20301-1200 HEALTH AFFAIRS SEP 3 0 2009 MEMORANDUM FOR ASSISTANT SECRETARY OF DEFENSE (RESER VE AFFAIRS) SURGEON GENERAL OF THE ARMY SURGEON GENERAL

More information

Core Standard 24. Cass Sandmann Emergency Planning Officer. Pat Fields Executive Director for Pandemic Flu Planning

Core Standard 24. Cass Sandmann Emergency Planning Officer. Pat Fields Executive Director for Pandemic Flu Planning Trust Board Meeting Agenda Item 7 Date: 30 September 2009 Title of Report Recommendations (please outline the purpose of the report and the key issues for consideration/decision) Progress with Pandemic

More information

A multidisciplinary scientifically independent network of. European Scientists Fighting Influenza 2014

A multidisciplinary scientifically independent network of. European Scientists Fighting Influenza 2014 European Scientists Fighting Influenza 2014 A multidisciplinary scientifically independent network of Members: Independent influenza experts Advisors: experts with additional advisory roles Partners: patient

More information

Pandemic Influenza Preparedness. Vaccine Sharing. Robert Gatter Center for Health Law Studies

Pandemic Influenza Preparedness. Vaccine Sharing. Robert Gatter Center for Health Law Studies Pandemic Influenza Preparedness and the Global Stalemate over Vaccine Sharing Robert Gatter Center for Health Law Studies Saint Louis University GISN and Indonesia sprotests WHO member states share flu

More information

Avian Influenza A(H7N9) Overview

Avian Influenza A(H7N9) Overview Avian Influenza A(H7N9) Overview Side event organized by China and WHO 21 May 2013 1 Avian Influenza A(H7N9) Novel Coronavirus (ncov) World experiencing emergence of 2 exceptional new virus infections

More information

Access to clinical trial information and the stockpiling of Tamiflu. Department of Health

Access to clinical trial information and the stockpiling of Tamiflu. Department of Health MEMORANDUM FOR THE COMMITTEE OF PUBLIC ACCOUNTS HC 125 SESSION 2013-14 21 MAY 2013 Department of Health Access to clinical trial information and the stockpiling of Tamiflu 4 Summary Access to clinical

More information

Establishing human vaccine manufacturing in Southern Africa

Establishing human vaccine manufacturing in Southern Africa Engineering Conferences International ECI Digital Archives Vaccine Technology IV Proceedings Spring 5-21-2012 Establishing human vaccine manufacturing in Southern Africa Morena Makhoana The Biovac Institue

More information

Regulatory Preparedness for Human Pandemic Influenza Vaccines

Regulatory Preparedness for Human Pandemic Influenza Vaccines EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva - 8 to 12 October 2007 ENGLISH ONLY FINAL Version endorsed by ECBS Proposed Guidelines: Regulatory Preparedness for Human Pandemic Influenza Vaccines

More information

EMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS

EMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS European Medicines Agency London, 21 August 2006 Doc. Ref. EMEA/214301/2006 EMEA PANDEMIC INFLUENZA CRISIS MANAGEMENT PLAN FOR THE EVALUATION AND MAINTENANCE OF PANDEMIC INFLUENZA VACCINES AND ANTIVIRALS

More information

GAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment

GAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment GAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment Tania Cernuschi Third Regional Pneumococcal Symposium, Istanbul, 13th - 14th February 2008 1 The GAVI Alliance Public-private

More information

DCVMN Perspective: Barriers and how developing countries manufacturers will be able to reach goal.

DCVMN Perspective: Barriers and how developing countries manufacturers will be able to reach goal. DCVMN Perspective: Barriers and how developing countries manufacturers will be able to reach goal. Dr. Suresh Jadhav Executive Director Serum Institute of India Limited. ssj@seruminstitute.com H1N1 Pandemic:

More information

Ebola: preparedness and solidarity. Ebola virus disease has claimed more than lives. and infected more than people in West Africa

Ebola: preparedness and solidarity. Ebola virus disease has claimed more than lives. and infected more than people in West Africa Ebola: preparedness and solidarity Introduction 1. Testing outbreak preparedness 2. Introducing a team approach for the global response 3. WEST stories from the field 4. What we have learnt Ebola virus

More information

H1N1 Planning, Response and Lessons to Date

H1N1 Planning, Response and Lessons to Date H1N1 Planning, Response and Lessons to Date Glen Nowak, Ph.D. Acting Director Division of News and Electronic Media Centers for Disease Control and Prevention The Beginning Mid-April indications that we

More information

Establishing a cholera stockpile: What do we need? Alejandro Costa Epidemic Readiness and Intervention

Establishing a cholera stockpile: What do we need? Alejandro Costa Epidemic Readiness and Intervention Establishing a cholera stockpile: What do we need? Alejandro Costa Epidemic Readiness and Intervention Outline 1. Experience Meningococcal vaccine stockpile Yellow Fever vaccine stockpile 2. Criteria for

More information

THE COMPLEX JOURNEY OF A VACCINE PART I The manufacturing chain, regulatory requirements and vaccine availability

THE COMPLEX JOURNEY OF A VACCINE PART I The manufacturing chain, regulatory requirements and vaccine availability THE COMPLEX JOURNEY OF A VACCINE PART I The manufacturing chain, regulatory requirements and vaccine availability International Federation of Pharmaceutical Manufacturers & Associations THE COMPLEX JOURNEY

More information

Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary

Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary Centers for Disease Control and Prevention (CDC) FY 2009 Budget Request Summary The President s FY 2009 Budget Request for the Centers for Disease Control and Prevention (CDC) discretionary funding is

More information

Pandemic Preparedness: Pigs, Poultry, and People versus Plans, Products, and Practice

Pandemic Preparedness: Pigs, Poultry, and People versus Plans, Products, and Practice SUPPLEMENT ARTICLE Pandemic Preparedness: Pigs, Poultry, and People versus Plans, Products, and Practice Julie L. Gerberding Centers for Disease Control and Prevention, Atlanta, Georgia Influenza pandemic

More information

Business Continuity and Crisis Management. Cardinal Health s Approach

Business Continuity and Crisis Management. Cardinal Health s Approach Business Continuity and Crisis Management Cardinal Health s Approach Welcome We don t have ALL the answers Opportunity to share ideas Discussion around how we can work together to help prepare our communities,

More information

Chapter 3: Roles and Responsibilities

Chapter 3: Roles and Responsibilities Chapter 3: Roles and Responsibilities Chapter 3: Roles and Responsibilities Page 3-1 Chapter 3: Roles and Responsibilities Table of Contents 1.0 Introduction 2.0 International World Health Organization

More information

Being Ready for the Next Pandemic: Expanded Access to Pandemic Vaccines

Being Ready for the Next Pandemic: Expanded Access to Pandemic Vaccines Being Ready for the Next Pandemic: Expanded Access to Pandemic Vaccines Coordination Between Public Health and Pharmacies Sam Graitcer, MD Immunization Services Division, NCIRD CDC Pandemic Influenza Vaccine

More information

PANDEMIC INFLUENZA IN THE WORKPLACE

PANDEMIC INFLUENZA IN THE WORKPLACE PANDEMIC INFLUENZA IN THE WORKPLACE 1 WILLIAM CANDLER, D.O., M.T.M.& H. Medical Director John Deere Harvester Works, Seeding Group and Cylinder Division Proposed Crisis Management Structure CORPORATE CRISIS

More information

EVALUATION OF HEALTH THREATS: How the EU system functions Zsuzsanna Jakab, Director of ECDC, Informal Meeting of Health Ministers

EVALUATION OF HEALTH THREATS: How the EU system functions Zsuzsanna Jakab, Director of ECDC, Informal Meeting of Health Ministers EVALUATION OF HEALTH THREATS: How the EU system functions Zsuzsanna Jakab, Director of ECDC, Informal Meeting of Health Ministers Angers, 8 9 September 2008 ecdc.europa.eu Key message of presentation ECDC

More information

Perspectives from regions: successes and challenges in promoting seasonal influenza vaccine usage in the EU

Perspectives from regions: successes and challenges in promoting seasonal influenza vaccine usage in the EU Perspectives from regions: successes and challenges in promoting seasonal influenza vaccine usage in the EU N. Safrany European Commission Pr. A. Nicoll ECDC 2 nd WHO GAP mtg 12-14 July 2011 Background

More information

PANDEMIC INFLUENZA PREPAREDNESS: STATE CHALLENGES

PANDEMIC INFLUENZA PREPAREDNESS: STATE CHALLENGES PANDEMIC INFLUENZA PREPAREDNESS: STATE CHALLENGES A Presentation to the Council of State Governments Health Policy Forum by Jeffrey Levi, Ph.D., Executive Director Trust for America s Health June 23, 2006

More information

ANNEX I. Template for Country Plan Matrix

ANNEX I. Template for Country Plan Matrix Pandemic Influenza Preparedness & Response: Guidance and Template for Country Planning By Humanitarian Organizations On Overarching Actions & Public Health Interventions Humanitarian Pandemic Preparedness

More information

What Antivirals Can Be Used for 2009 H1N1 Influenza?

What Antivirals Can Be Used for 2009 H1N1 Influenza? www.upmc-biosecurity.org www.upmc-cbn.org May 13, 2009 The Use of Antivirals for 2009 H1N1 Influenza Virus Infection By Ann Norwood, MD, Brooke Courtney, JD, MPH, Eric Toner, MD, and Amesh Adalja, MD Use

More information